Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
217 stopped studies mapped to Malignant Soft Tissue Neoplasm and descendants · 91% state a reason
Over the 217 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | Phase 3 | terminated | Aug 7, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | Phase 1 | terminated | Jul 27, 2018 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate further development of the program. | Sponsor / business decision |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT06252727 | Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) | Phase 1 | withdrawn | Feb 12, 2024 | University of California, Davis | PI choice. | Other (stated, no rule matched) |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab… | Phase 3 | withdrawn | Apr 17, 2024 | Boehringer Ingelheim | Sponsor decision. | Sponsor / business decision |
| NCT04879979 | GIST and Memory and Attention Adaptation Training(GIST-MAAT) | N/A | terminated | May 10, 2021 | University of Pittsburgh | Slow enrollment | Enrollment / accrual |
| NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly…(METROPHOLYS) | Phase 3 | terminated | Dec 7, 2020 | Istituto Oncologico Veneto IRCCS | enrollment too slow to reach the target in a reasonable time frame | Enrollment / accrual |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | Phase 1 | terminated | May 19, 2021 | Fred Hutchinson Cancer Center | Terminated due to end of funding | Funding |
| NCT03132155 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | Phase 2 | terminated | Apr 27, 2017 | NantPharma, LLC | Prematurely terminated due to lack of therapeutic effect | Other (stated, no rule matched) |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | — | terminated | Jul 2, 2019 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Lack of recruitment | Enrollment / accrual |
| NCT05043649 | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Phase 1 | terminated | Sep 14, 2021 | Monopar Therapeutics | lack of timely enrollment | Enrollment / accrual |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase 1 | terminated | Sep 13, 2018 | Fred Hutchinson Cancer Center | The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was… | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Phase 1 | terminated | May 26, 2021 | Pyramid Biosciences | Sponsor terminated development of PBI-200 | Other (stated, no rule matched) |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Phase 1 | terminated | Nov 1, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT02706171 | Stereotactic Radiosurgery for Soft Tissue Sarcoma | N/A | withdrawn | Mar 11, 2016 | The Cooper Health System | not stated | Not stated |
| NCT04553744 | Identification of Surgical Management of Lymph Node Basins and Surgical Practice Patterns… | — | withdrawn | Sep 17, 2020 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft…(Tolerance) | Phase 3 | terminated | Mar 3, 2021 | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawal grant provider | Other (stated, no rule matched) |
| NCT04176016 | Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2019 | OncoTherapy Science, Inc. | Some of the raw materials for the investigational drug are difficult to obtain and expensive. | Other (stated, no rule matched) |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma(ACCeSs) | Phase 2 | terminated | Feb 18, 2020 | Italian Sarcoma Group | Difficulty of enrollment | Enrollment / accrual |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT05154630 | Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced… | Phase 1 / Phase 2 | terminated | Dec 13, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The sponsor has decided to terminate this study based on the current clinical research status of… | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women… | Phase 4 | withdrawn | Sep 16, 2005 | Imperial College London | Recruitment not possible worldwide | Enrollment / accrual |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | Phase 2 | withdrawn | Dec 30, 2021 | David Liebner, MD | PI decision | Other (stated, no rule matched) |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial… | Phase 1 / Phase 2 | terminated | Oct 31, 2019 | Eli Lilly and Company | Study terminated for meeting protocol specified futility criteria. | Efficacy / futility |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric… | Phase 1 | terminated | Aug 31, 2015 | AeRang Kim | low accrual | Enrollment / accrual |
| NCT01367301 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | N/A | terminated | Jun 7, 2011 | Albert Einstein College of Medicine | Lack of accrual. PI left the institution | Investigator |
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With… | N/A | terminated | Oct 9, 2013 | Albert Einstein College of Medicine | Study terminated due to low accrual. PI left the institution | Investigator |
| NCT05026502 | A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of…(REACH) | — | terminated | Aug 30, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | N/A | terminated | Aug 29, 2019 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer,… | N/A | terminated | Aug 15, 2018 | Roswell Park Cancer Institute | Diagnostic issues | Other (stated, no rule matched) |
| NCT03867188 | Liposomal Bupivacaine (Exparel) in Sarcomas | Early Phase 1 | terminated | Mar 7, 2019 | Wake Forest University Health Sciences | Enrollment of eligible subjects, delays due to the COVID-19 Virus, and lack of funding | COVID-19 / pandemic |
| NCT04877587 | Gemcitabine With Ascorbate Including Adolescents | Early Phase 1 | withdrawn | May 7, 2021 | David Dickens | Unable to enroll | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT05302570 | Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS(PROTONS-RPS) | Phase 2 | withdrawn | Mar 31, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | withdrawn by PI | Other (stated, no rule matched) |
| NCT03921073 | Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | Phase 2 | terminated | Apr 19, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor Terminated Funding | Funding |
| NCT02987959 | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Phase 2 | terminated | Dec 9, 2016 | Fox Chase Cancer Center | Closed to accrual due to Funding Sponsor withdrawing support due to low accrual | Enrollment / accrual |
| NCT00140855 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | Phase 2 | terminated | Sep 1, 2005 | Ludwig Institute for Cancer Research | Study discontinued due to poor accrual. | Enrollment / accrual |
| NCT03524898 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | terminated | May 15, 2018 | Swiss Cancer Institute | As Last patient last visit (LPLV) took place on 15/02/2022, the trial was ended prematurely on this… | Other (stated, no rule matched) |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or… | Phase 1 / Phase 2 | terminated | Nov 10, 2015 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03400956 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT03641326 | Sunitinib in Sarcomas of the Central Nervous System | Phase 2 | terminated | Aug 22, 2018 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT03916796 | Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With… | N/A | terminated | Apr 16, 2019 | Washington University School of Medicine | Too many barriers to enrolling well going forward | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 28, 2024source: clinicaltrials